ZVRA — Zevra Therapeutics Cashflow Statement
0.000.00%
- $685.14m
- $682.59m
- $23.61m
Annual cashflow statement for Zevra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -12.8 | -8.55 | -41.5 | -46 | -106 |
Depreciation | |||||
Non-Cash Items | 10.2 | 19.1 | 26.1 | 8.86 | 36.5 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.374 | -0.357 | -4.25 | 2.65 | -7.07 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -1.94 | 10.4 | -18.7 | -33.5 | -69.7 |
Capital Expenditures | -0.033 | -0.102 | -0.093 | -0.296 | -6 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | -15.4 | -36.6 | -17.1 | -16.2 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.033 | -15.5 | -36.7 | -17.4 | -22.2 |
Financing Cash Flow Items | -0.118 | 73.9 | -0.033 | 0.692 | -1.44 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.74 | 113 | 8.35 | 28.5 | 82.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.767 | 108 | -46.9 | -22.4 | -9.26 |